Safety, Tolerability and Pharmacokinetics of KBP-7072

Phase 1 Completed 46 enrolled KBP Biosciences

RandomizedParallel-groupDouble-blindTreatment

Summary

This is a randomized, double-blind, placebo-controlled, dose-escalation study to evaluate the safety, tolerability and pharmacokinetics of a single dose of KBP-7072 following oral single ascending dose administration and with an open label food effect panel.

Timeline

Start: 2015-05
Primary completion: 2015-10
Completion: 2015-12

Publications

Huband MD, Mendes RE, Pfaller MA, Lindley JM, Strand GJ, Benn VJ, Zhang J, Li L, Zhang M, Tan X, Liu Q, Flamm RK. In Vitro Activity of KBP-7072, a Novel Third-Generation Tetracycline, against 531 Recent Geographically Diverse and Molecularly Characterized Acinetobacter baumannii Species Complex Isolates. Antimicrob Agents Chemother. 2020 Apr 21;64(5):e02375-19. doi: 10.1128/AAC.02375-19. Print 2020 Apr 21.

Drugs

Evaluation	Drug	Modality	Dose	Route
Subject	KBP-7072	Small molecule	—	Oral

Indications

No indication recorded.